Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Two regenerative aesthetic and longevity products, with clinically validated ingredients, are expected to reach the U.S. market during 2026,entering a rapidly expanding U.S. medical aesthetics market, projected to reach $90 billion by 2030 HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food